Long‐Term Safety Profile of Ruxolitinib in Chronic Myeloproliferative Neoplasms: A Comprehensive Real‐World Analysis
Open Access
Abstract
Introduction: Ruxolitinib is a key therapeutic option for patients with myeloproliferative neoplasms. Its short‐term toxicity profile is well‐established, but long‐term safety data remains scarce. Methods: We aimed to evaluate toxicity associated with long‐term exposure to ruxolitinib (defined as 3 years or longer) through a dual‐cohort retrospective study combining a local cohort from Hospital 12 de Octubre with a large real‐world dataset from TriNetX database. The selected outcomes were non‐melanoma skin cancer (NMSC), other secondary malignancies and infections (zoster, urinary tract infection, pneumonia and sepsis). Results: With a median treatment time of 61.5 months in the local cohort ( n = 36), infections were common (72.2% of patients), with occurrence of late‐onset opportunistic infections such as disseminated mycobacterial disease. A total of 19.4% of patients developed NMSC and 11.1% other secondary malignancies. In the TriNetX cohort, after propensity score matching ( n = 2579), patients with ≥ 3 years of ruxolitinib showed a higher risk of NMSC, zoster, urinary tract infection, pneumonia and sepsis. No significant increase in other tumours was observed. Conclusion: Our findings suggest that extended ruxolitinib therapy is associated with specific long‐term risks, particularly NMSC and zoster reactivation, while not increasing the incidence of secondary malignancies. These results support continued vigilance and preventive strategies in the setting of long‐term ruxolitinib exposure. Trial Registration: The authors have confirmed clinical trial registration is not needed for this submissionKeywords
This publication has 50 references indexed in Scilit:
- Myeloproliferative NeoplasmsNew England Journal of Medicine, 2017
- Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trialJournal of Hematology & Oncology, 2017
- Risk factors for infections in myelofibrosis: role of disease status and treatment. A multicenter study of 507 patientsAmerican Journal of Hematology, 2016
- Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosisLeukemia, 2016
- Risk and Cause of Death in Patients Diagnosed With Myeloproliferative Neoplasms in Sweden Between 1973 and 2005: A Population-Based StudyJournal of Clinical Oncology, 2015
- Jakafi (Ruxolitinib): First FDA-Approved Medication for the Treatment of Patients with Polycythemia Vera.2015
- Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia VeraNew England Journal of Medicine, 2015
- Management of cytopenias in patients with myelofibrosis treated with ruxolitinib and effect of dose modifications on efficacy outcomesOncoTargets and Therapy, 2013
- Ruxolitinib: The First FDA Approved Therapy for the Treatment of MyelofibrosisClinical Cancer Research, 2012
- Increased risk of lymphoid neoplasm in patients with myeloproliferative neoplasm: a study of 1,915 patientsHaematologica, 2010